Glazer Capital LLC’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Glazer Capital LLC’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,254,733	Closed	-$12.7M	–	518
2022 Q4	$12.7M	Buy	1,254,733 +259,259	+26%	+$2.59M	0.33%	106
2022 Q3	$9.86M	Buy	995,474 +287,251	+41%	+$2.83M	0.18%	174
2022 Q2	$6.93M	Buy	708,223 +523,267	+283%	+$5.12M	0.17%	188
2022 Q1	$1.8M	Buy	184,956 +183,013	+9,419%	+$1.78M	0.05%	262
2021 Q4	$19K	Hold	1,943	–	–	﹤0.01%	776
2021 Q3	$19K	Buy	1,943 +1,906	+5,151%	+$18.4K	﹤0.01%	869
2021 Q2	$0	Buy	+37	New	+$363	﹤0.01%	993

Glazer Capital LLC's EBAC Position: Q1 2023 in Review

Glazer Capital LLC sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 1,254,733 shares — an estimated $12.7M sold.

Glazer Capital LLC first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $12.7M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Glazer Capital LLC reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Glazer Capital LLC sold 1,254,733 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $12.7M.
Glazer Capital LLC first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Glazer Capital LLC's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $12.7M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Glazer Capital LLC's 13F filing for Q1 2023, filed 15 May 2023.